Organon & Co.
For the period ended Jun 30, 2026. Filed Jul 31, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Jul 31, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Third-Party Arrangements
- Third-Party Arrangements
On June 2, 2021, Organon and Merck entered into a Separation and Distribution Agreement (the “Separation and Distribution Agreement”). Pursuant to the Separation and Distribution Agreement, Merck agreed to spin off the Organon products into Organon, a new, publicly-traded company (the “Separation”).
The Separation was completed pursuant to the Separation and Distribution Agreement and other agreements with Merck related to the Separation. As of June 30, 2026, only one jurisdiction remains under an Interim Operating Model Agreement.
Under the manufacturing and supply agreements, the Company manufactures certain products for Merck, or its applicable affiliate, and Merck manufactures certain products for the Company, or its applicable affiliate. For details on the rights and responsibilities of the parties under the agreements, refer to Note 17 “Third-Party Arrangements” to the audited Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.
The amounts due under such agreements were:
| ($ in millions) | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Due from Merck in Accounts receivable | $143 | $98 |
| Due to Merck in Accounts payable | 374 | 337 |
-21-
Sales and cost of sales resulting from the manufacturing and supply agreements with Merck were:
| Three Months EndedJune 30, | Six Months EndedJune 30, | |||
|---|---|---|---|---|
| ($ in millions) | 2026 | 2025 | 2026 | 2025 |
| Sales | $13 | $19 | $26 | $37 |
| Cost of sales | 10 | 16 | 21 | 32 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.